| target_debate_target | Should LAMP1 (Lysosomal associated membrane protein 1) be prioritized as a thera | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| sess_SDA-2026-04-04- | Epigenetic reprogramming of aging neurons represents an active research focus wi | 0.67 | 7 | 4 | completed | 2026-04-22 | SDA-2026-04-04-gap-20260404-060512 |
| target_debate_target | Should AHR (Aryl hydrocarbon receptor) be prioritized as a therapeutic target fo | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should BMAL1 (Basic Helix-Loop-Helix ARNT Like 1) be prioritized as a therapeuti | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| sess_SDA-2026-04-04- | APOE4 is the strongest genetic risk factor for late-onset AD. How APOE4 specific | 0.78 | 7 | 4 | completed | 2026-04-22 | SDA-2026-04-04-gap-apoe4-lipid-metabolism |
| target_debate_target | Should VCP (Valosin containing protein) be prioritized as a therapeutic target f | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should NAMPT (Nicotinamide phosphoribosyltransferase) be prioritized as a therap | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| sess_SDA-2026-04-04- | Tau pathology spreads through synaptically connected brain regions in Alzheimer | 0.78 | 7 | 4 | completed | 2026-04-22 | SDA-2026-04-04-gap-tau-prion-spreading |
| target_debate_target | Should CRH (Corticotropin Releasing Hormone) be prioritized as a therapeutic tar | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should C1QA (Complement C1q A Chain) be prioritized as a therapeutic target for | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| sess_SDA-2026-04-04- | Investigate mechanisms of epigenetic reprogramming in aging neurons | 0.79 | 7 | 4 | completed | 2026-04-22 | SDA-2026-04-04-gap-20260404-120802 |
| target_debate_target | Should ALOX15 (15-lipoxygenase) be prioritized as a therapeutic target for neuro | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should CLOCK (Circadian Locomotor Output Cycles Kaput) be prioritized as a thera | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| sess_SDA-2026-04-04- | Lysosomal membrane permeabilization releasing cathepsins triggers NLRP3 inflamma | 0.76 | 7 | 4 | completed | 2026-04-22 | SDA-2026-04-04-gap-lysosomal-cathepsin-ad |
| target_debate_target | Should CMKLR1 (Chemokine-like Receptor 1) be prioritized as a therapeutic target | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| sess_SDA-2026-04-06- | The study establishes G3BP1's role as a tunable switch for stress granule assemb | 0.69 | 7 | 4 | completed | 2026-04-22 | SDA-2026-04-06-gap-pubmed-20260406-041428-e14e6524 |
| target_debate_target | Should SDC1 (Syndecan-1) be prioritized as a therapeutic target for neurodegener | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should RAB27A (Ras-related protein Rab-27A) be prioritized as a therapeutic targ | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| sess_SDA-2026-04-06- | While single-cell sequencing reveals microglial heterogeneity across regions, ag | 0.73 | 7 | 4 | completed | 2026-04-22 | SDA-2026-04-06-gap-pubmed-20260406-041439-ec89b1e4 |
| target_debate_target | Should MCOLN1 (Mucolipin-1) be prioritized as a therapeutic target for neurodege | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| sess_SDA-2026-04-06- | The debate highlighted IGFBPL1's potential as a microglial master regulator but | 0.69 | 7 | 4 | completed | 2026-04-22 | SDA-2026-04-06-gap-debate-20260406-062045-6addd0cf |
| target_debate_target | Should HK2 (Hexokinase 2) be prioritized as a therapeutic target for neurodegene | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| sess_SDA-2026-04-06- | The debate highlighted that most promising targets (VAMP2, ESCRT, fascin-1) are | 0.75 | 5 | 4 | completed | 2026-04-22 | SDA-2026-04-06-gap-debate-20260406-062052-7bcf4b6c |
| target_debate_target | Should LRP1 (LDL receptor related protein 1) be prioritized as a therapeutic tar | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should AQP1 (Aquaporin-1) be prioritized as a therapeutic target for neurodegene | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should TGFB1 (Transforming growth factor beta-1) be prioritized as a therapeutic | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| sess_SDA-2026-04-06- | The debate revealed that microglial senescence markers are poorly defined compar | 0.72 | 7 | 4 | completed | 2026-04-22 | SDA-2026-04-06-gap-debate-20260406-062101-6af4ba5f |
| sess_SDA-2026-04-06- | The study shows SPP1 from perivascular cells drives microglial synaptic engulfme | 0.70 | 7 | 4 | completed | 2026-04-22 | SDA-2026-04-06-gap-pubmed-20260406-062118-e3613755 |
| sess_SDA-2026-04-06- | The debate focused on therapeutic targets but did not address how to identify pa | 0.75 | 7 | 4 | completed | 2026-04-22 | SDA-2026-04-06-gap-debate-20260406-062039-3b945972 |
| sess_SDA-2026-04-06- | The study shows TRIM21 and autophagy receptors can eliminate both physiological | 0.75 | 7 | 4 | completed | 2026-04-22 | SDA-2026-04-06-gap-pubmed-20260406-041423-3a6aa4ab |
| sess_SDA-2026-04-06- | The study shows stress granules are dynamic and reversible assemblies, but in ne | 0.84 | 7 | 4 | completed | 2026-04-22 | SDA-2026-04-06-gap-pubmed-20260406-041428-4c4414ad |
| sess_SDA-2026-04-06- | The abstract identifies dystrophic microglia as senescent cells in aged brains b | 0.79 | 7 | 4 | completed | 2026-04-22 | SDA-2026-04-06-gap-pubmed-20260406-041439-5f43216e |
| sess_SDA-2026-04-06- | Multiple hypotheses assumed microglia could be restored to homeostatic states, b | 0.63 | 7 | 4 | completed | 2026-04-22 | SDA-2026-04-06-gap-debate-20260406-062045-7a6cf14e |
| sess_SDA-2026-04-06- | While DNAJB1 enhancement showed promise, the debate raised concerns about whethe | 0.73 | 7 | 4 | completed | 2026-04-22 | SDA-2026-04-06-gap-debate-20260406-062052-28cbc764 |
| sess_SDA-2026-04-06- | The debate identified APOE4 astrocytes as potential senescence drivers but did n | 0.76 | 7 | 4 | completed | 2026-04-22 | SDA-2026-04-06-gap-debate-20260406-062101-5d7b9dc0 |
| sess_SDA-2026-04-06- | The abstract indicates SPP1 upregulation occurs in perivascular macrophages and | 0.67 | 7 | 4 | completed | 2026-04-22 | SDA-2026-04-06-gap-pubmed-20260406-062118-5e49e14f |
| target_debate_target | Should ANXA1 (Annexin A1) be prioritized as a therapeutic target for neurodegene | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should FOXO3 (Forkhead box protein O3) be prioritized as a therapeutic target fo | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should ABCA1 (ATP-binding cassette transporter A1) be prioritized as a therapeut | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should ANGPT1 (Angiopoietin-1) be prioritized as a therapeutic target for neurod | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should HDAC3 (Histone Deacetylase 3) be prioritized as a therapeutic target for | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should SRPK1 (SRSF protein kinase 1) be prioritized as a therapeutic target for | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should EPHB4 (Ephrin type-B receptor 4) be prioritized as a therapeutic target f | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should ALOX5 (5-lipoxygenase) be prioritized as a therapeutic target for neurode | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should GPX4 (Glutathione peroxidase 4) be prioritized as a therapeutic target fo | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should GPR37 (G-protein coupled receptor 37) be prioritized as a therapeutic tar | 0.50 | 0 | 4 | completed | 2026-04-22 | |
| target_debate_target | Should DNMT1 (DNA methyltransferase 1) be prioritized as a therapeutic target fo | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| target_debate_target | Should BACE1 (Beta-secretase 1) be prioritized as a therapeutic target for neuro | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| target_debate_target | Should STING1 (Stimulator of interferon genes protein 1) be prioritized as a the | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| target_debate_target | Should PPARGC1A (Peroxisome proliferator-activated receptor gamma coactivator 1- | 0.50 | 0 | 4 | completed | 2026-04-21 | |